AHS 淋巴瘤干细胞移植 PPT课件

m Cell Transplants in the United States, 2010?(Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants)РSUM12_28.pptРSlide 8РNumber of TransplantsР1. HL,霍奇金淋巴瘤Р中山大学肿瘤医院?SUN YAT-SEN UNIVERSITY CANCER CENTERРHL :ASCT 综合治疗效果Р复发/耐药: ?CR 34-80 % ?长期生存率: 25- 50%? 早期死亡率:4-21%?复发/耐药:?10年生存率:50% ?10y PFS: 45% ? 10y RFS: 23%?首次复发:?5年PFS 30 –52%, ?5年生存率: 34-60%Р1998-2009?100 pts?BuMelTt(busulfan, melphalan,thiotepa): 60pts?Others:40pts?CBV(21)?TBICyE(14)?BEAM(4)?Melphalan(1)Р5 yr-OS 73% VS. 44%?5 yr-PFS 66% VS. 37%РNo differences in toxicity and? NRMРImproved e with busulfan, melphalan and thiotepa conditioning in AHSCT for ?relapsed/refractory HLРTarunpreet B. Leukemia & Lymphoma, 2014; 55(3): 583–587РPFSРOSРP=0.03РP=0.05Р2. NHL, DLBCL弥漫大B淋巴瘤Р中山大学肿瘤医院?SUN YAT-SEN UNIVERSITY CANCER CENTER